Abstract Number: 1108 • ACR Convergence 2023
Minimal Clinically Important Difference (MCID) of Quality of Life Assessments in Patients with Uncontrolled Gout
Background/Purpose: Gout is an inflammatory arthritis that results in severe joint inflammation, pain, disability, and lower quality of life (QoL). Determining minimal clinically important differences…Abstract Number: 1888 • ACR Convergence 2023
Solving the Final Puzzle of Gout Detection in DECT via Machine Learning-Based Mitigation of Pseudolesion-Related Challenges: Enhancing Diagnostic Accuracy
Background/Purpose: In a recent study, the low specificity of Dual-Energy CT (DECT) has raised concerns due to the frequent occurrence of pseudo lesions, also referred…Abstract Number: 0237 • ACR Convergence 2023
Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database
Background/Purpose: Pegloticase, a recombinant pegylated uricase, rapidly reduces serum urate (SU) in patients refractory to/intolerant of oral urate-lowering therapies (ULTs).1,2 However, pegloticase is generally used…Abstract Number: 0753 • ACR Convergence 2023
Facility Variation in HLA-B*58:01 Allele Testing for Asian and Black Patients Receiving Allopurinol in the Veterans Affairs Healthcare System
Background/Purpose: New guidelines published in 2020 conditionally recommend HLA-B*58:01 allele testing for South Asian and Black patients receiving allopurinol to reduce the risk of severe…Abstract Number: 1109 • ACR Convergence 2023
Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant Hypothesis
Background/Purpose: Hyperuricemia is a central feature in the pathogenesis of gout. Hyperuricemia results from an imbalance between endogenous production and excretion of urate; however, the…Abstract Number: 1909 • ACR Convergence 2023
Identifying and Addressing Suboptimal Urate Lowering Therapy in Gout Patients with Chronic Kidney Disease
Background/Purpose: Patients with gout and chronic kidney disease (CKD) are often not appropriately managed with goal-directed urate-lowering therapy (ULT). To address deficits in management of…Abstract Number: 0238 • ACR Convergence 2023
Adherence to the Gout and Crystal Arthritis Network (G-CAN) Consensus Statements for Gout Nomenclature
Background/Purpose: Uniform terminology with standardised definitions for the various elements and states of a disease ensure accurate and consistent technical communication. In 2019 the Gout…Abstract Number: 0811 • ACR Convergence 2023
Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate (primary prevention); however, whether this translates into preventing recurrent flares among gout patients (secondary prevention) and gout-primary…Abstract Number: 1110 • ACR Convergence 2023
Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout
Background/Purpose: In early phase studies AR882 exhibited good dose proportionality, long half-life and dose-dependent serum urate (sUA) lowering effect in a broad range of doses…Abstract Number: 2428 • ACR Convergence 2023
Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors
Background/Purpose: A recent UK study reported a transient increased cardiovascular risk after gout flare episodes [Cipolletta et al. JAMA 2022], which may translate to premature…Abstract Number: 0222 • ACR Convergence 2022
Primary Care Provider Utilization of Musculoskeletal Ultrasound for the Diagnosis of Acute Gout Flares: A Novel Opportunity for Rheumatology-Focused Educational Curricula
Background/Purpose: Gout, the most common inflammatory arthritis, can be challenging to identify, especially when clinical criteria are insufficient to support a diagnosis. Musculoskeletal ultrasound (MSK…Abstract Number: 1787 • ACR Convergence 2022
The Impact of Topically Applied pH Modulator on Acute Inflammatory Pain, Serum Calcium, and C-Reactive Protein (CRP) During an Acute Gout Flare – a Phase 2a Randomized, Double-Blind, Placebo-Controlled Study
Background/Purpose: Inflammatory cytokine-mediated bone resorption increases serum calcium (Ca2+) and can lead to calcification at chronically inflamed sites. Ca2+ influences cytokine activity to intensify the…Abstract Number: 1806 • ACR Convergence 2022
Characteristics and Comorbidity Burden of Phase 3 Clinical Trial Participants Who Did and Did Not Experience Acute Gout Flares During Biweekly Pegloticase Dosing
Background/Purpose: Acute gout flare often accompanies urate-lowering therapy initiation and is the most common adverse event associated with pegloticase, a recombinant pegylated uricase that rapidly…Abstract Number: 1826 • ACR Convergence 2022
Association of High Uric Acid Levels with Low Bone Mineral Density in Pre- but Not Post-menopausal Women with Rheumatoid Arthritis
Background/Purpose: Uric acid is controversially discussed regarding its effect on bone health. Higher uric acid levels have been associated with higher T-scores and fewer bone…Abstract Number: 0550 • ACR Convergence 2022
Improving the Accuracy of Automated Gout Flare Ascertainment Using Natural Language Processing of Medical Records and Linked Medicare Claims Data for Real-world Comparative Effectiveness Research
Background/Purpose: Gout flares are challenging to study using large real-world data because flares are episodic with varying severity and clinical manifestations. Furthermore, there is no…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 45
- Next Page »